CARR Biosystems
CARR Biosystems designs and sells tubular-bowl centrifuge systems (single-use UniFuge and stainless steel PowerFuge/ViaFuge families) for bioprocessing, serving cell therapy, gene therapy, biologics, vaccine, nucleic acid, cellular agriculture, and microbial fermentation manufacturers via direct enterprise sales.
- Company typePrivate
- Founded1993
- HeadquartersClearwater, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CARR Biosystems does
CARR Biosystems is a US-based bioprocessing equipment manufacturer that designs and sells tubular-bowl centrifuge systems for life sciences and specialty chemical customers. The company was founded in 1993 as CARR Separations, acquired by Kendro Laboratories in 2000, acquired by Barry-Wehmiller Companies in 2004 (with operations relocated to Clearwater, Florida), and rebranded to its current name in 2022; it operates today as a privately held subsidiary of Barry-Wehmiller.
The company's product portfolio is organized into two lines: a single-use platform (UniFuge family — UFMini, UniFuge Pilot, and U2K, with working volumes from 90 mL to 9 L and flow rates up to 20 L/min) and a stainless steel platform (PowerFuge and ViaFuge families, with bowl capacities up to 36 L and flow rates up to 1,700 L/hr). Both lines use low-shear tubular bowl centrifugation, with single-use modules that are gamma-irradiated, RFID-tagged for traceability, and operated via PLC (Allen-Bradley or Siemens) with optional SCADA over Ethernet and 21 CFR Part 11 compliance. The manufacturer cites up to 98% cell recovery and 90–95% viability in cell processing, with reported gains over depth filtration in HEK293 viral titer (46% increase) and UFMini throughput (46 → 59 L/m²).
CARR sells exclusively through direct enterprise sales with quote-based pricing and multi-year contract cadence, targeting biopharmaceutical manufacturers across cell therapy (CAR-T, NK, iPSC, MSC), gene therapy (viral vectors, plasmid DNA), biologics (mAb clarification, recombinant proteins), vaccines, nucleic acids, cellular agriculture, and microbial fermentation. The company holds an extensive patent portfolio (multiple granted US patents and equivalents in Canada, Japan, Korea, India, and Australia) and an 11-trademark brand portfolio, but discloses no revenue, customer logos, or AI/ML capabilities in the source material.
CARR Biosystems firmographics
Firmographics- Name
- CARR Biosystems
- Legal name
- CARR Biosystems
- Website
- https://carrbiosystems.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- CARR Biosystems designs and sells tubular-bowl centrifuge systems (single-use UniFuge and stainless steel PowerFuge/ViaFuge families) for bioprocessing, serving cell therapy, gene therapy, biologics, vaccine, nucleic acid, cellular agriculture, and microbial fermentation manufacturers via direct enterprise sales.
- Ownership category
- akta.pro rank
CARR Biosystems industry classification
Industry- Product category
- Bioprocessing Centrifuge Equipment
- SIC
- General Industrial Machinery & Equipment (3560)
- akta.pro primary industry
- Biorefinery Co-product Recovery, Purification & Separation (Downstream Processing Systems) (EUAAAIAN)
Keywords
Where CARR Biosystems is headquartered
LocationHeadquarters
- HQ city
- Clearwater
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CARR Biosystems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Capital Equipment Sales: CARR Biosystems generates revenue through the sale of bioprocessing centrifuge equipment including single-use and stainless steel systems. Products are sold as capital equipment to biopharmaceutical and life sciences manufacturers. The revenue model involves direct enterprise sales with quotes, consultation, and demonstration processes. After-sale support and service are provided.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CARR Biosystems product offering
Product offeringCore offering
CARR Biosystems designs, manufactures, and sells centrifugal bioseparation systems for the biopharmaceutical and life sciences industries. Its product portfolio includes single-use centrifuges (UniFuge family: UFMini, UniFuge Pilot, U2K) and stainless steel centrifuges (PowerFuge and ViaFuge families) used for cell harvesting, cell washing, media exchange, buffer exchange, and concentration in cell therapy, gene therapy, biologics, vaccines, nucleic acid, cellular agriculture, and microbial fermentation applications.
Product overview
CARR Biosystems is a bioprocessing equipment company that offers two main product lines: the UniFuge family of single-use centrifuges (UFMini, UniFuge Pilot, U2K) and stainless steel centrifuges (PowerFuge and ViaFuge families). The UniFuge single-use platform uses tubular bowl centrifugation for low-shear separation, cell washing, media exchange, and concentration. The stainless steel PowerFuge and ViaFuge systems provide automated CIP/SIP capabilities for high-volume processing. All products use tubular bowl technology designed to preserve cell viability while achieving high recovery rates across applications including cell therapy, gene therapy, biologics, vaccines, and cellular agriculture.
Differentiator
Problem solved
Functional benefit
Brands
- UniFuge: Single-use separation systems for bioprocessing applications
- PowerFuge
- ViaFuge
- CARR
- CENTRITECH
- SOFTSTREAM
Products and services
- UniFuge Pilot A single-use centrifuge for early-stage development delivering low-shear, high-throughput processing with up to 98% cell viability. Features 1L or 1.8L bowl with 1-4 L/min flow rate, scalable from bench to pilot production.
- UFMini A single-use system designed for scale-down studies and small-to-mid-scale processing with high cell recovery. Features tubular bowl centrifugation for low-shear separation with 90mL or 300mL minimum working volume and 50-1000 mL/min flow rate.
- U2K
Quantifiable outcome
- Up to 98% cell recovery with less than 5% viability loss in cell processing applications
- +6 more outcomes
Companies that use CARR Biosystems
Customer profileSegments7 records
Ideal customer profiles7 records
CARR Biosystems technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
CARR Biosystems partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights4 records
CARR Biosystems competitors and assessment
Company assessmentDirect peers
- Alfa Laval: Alfa Laval is a direct peer in industrial and bioprocessing centrifugation, offering a broad range of separators and centrifuges used in pharmaceutical, biotech and food applications. It competes head-to-head with CARR's PowerFuge and ViaFuge stainless steel systems in high-volume bioprocessing.
- GEA Group: GEA is a direct competitor in industrial separation technology, including centrifuges used for biotech, pharma and fermentation clarification. Its separator portfolio overlaps directly with CARR's tubular bowl and stainless steel platforms.
- Andritz: Andritz Separation is a direct peer in industrial centrifugation for chemical, pharma and biotech applications. Its solid-bowl and decanter centrifuges compete with CARR's PowerFuge line in fermentation and biologics clarification.
- Eppendorf: Eppendorf is a direct peer in centrifugation and bioprocessing, offering benchtop and pilot centrifuges commonly used in cell therapy and biologics labs. Its single-use and reusable centrifuge systems overlap with CARR's UniFuge and ViaFuge product ranges.
- Beckman Coulter Life Sciences (Danaher): Beckman Coulter Life Sciences is a direct peer in laboratory and bioprocessing centrifugation, including high-speed centrifuges used in cell therapy and biologics development. Its systems overlap with CARR's ViaFuge and UniFuge platforms in life sciences applications.
Broad incumbents
- Sartorius: Sartorius is a broad incumbent bioprocessing equipment vendor whose portfolio spans upstream and downstream processing, including separation, filtration and single-use systems. It competes with CARR primarily at the U2K and UniFuge Pilot scale in cell and gene therapy applications.
- Cytiva (Danaher): Cytiva is a broad incumbent in bioprocessing, offering single-use solutions, filtration, and clarification systems. Its ÄKTA and single-use depth filtration products overlap with CARR's UniFuge in primary clarification and cell harvesting workflows.
- Thermo Fisher Scientific: Thermo Fisher is a broad incumbent in life sciences and bioprocessing, offering centrifuges, single-use systems, and downstream processing solutions through its Patheon and bioproduction arms. It is a competitor in both capital equipment and integrated bioprocessing workflows.
- Pall Corporation (Danaher): Pall is a broad incumbent in bioprocess filtration and separation, including depth filtration and centrifuge alternatives. Its clarification products directly compete with CARR's tubular bowl systems in primary recovery for cell cultures and fermentation.
Emerging players
- Repligen: Repligen is an emerging player in single-use bioprocessing, focused on filtration, chromatography and process analytics. Its single-use clarification and fluid management products overlap with CARR's UniFuge offering in upstream cell culture harvest.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CARR Biosystems social profiles
Digital presenceCARR Biosystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
CARR Biosystems leadership team
Management profileNumber of profiles
Profiles2 records
CARR Biosystems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CARR Biosystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CARR Biosystems
What does CARR Biosystems do?
CARR Biosystems designs, manufactures, and sells centrifugal bioseparation systems for the biopharmaceutical and life sciences industries. Its product portfolio includes single-use centrifuges (UniFuge family: UFMini, UniFuge Pilot, U2K) and stainless steel centrifuges (PowerFuge and ViaFuge families) used for cell harvesting, cell washing, media exchange, buffer exchange, and concentration in cell therapy, gene therapy, biologics, vaccines, nucleic acid, cellular agriculture, and microbial fermentation applications.
Is CARR Biosystems a public or private company?
CARR Biosystems is a private company. It is classified as corporate owned and is currently operating.
When was CARR Biosystems founded?
CARR Biosystems was founded in 1993. It employs 51 to 100 people.
Where is CARR Biosystems based?
CARR Biosystems is headquartered in Clearwater, United States, in the North America region.
How does CARR Biosystems make money?
One revenue line is on record: capital Equipment Sales.
Who are CARR Biosystems's main competitors?
Direct peers on record are Alfa Laval, GEA Group, Andritz, Eppendorf and Beckman Coulter Life Sciences (Danaher). Broad incumbents are Sartorius, Cytiva (Danaher), Thermo Fisher Scientific and Pall Corporation (Danaher). Repligen is listed as an emerging player.
Does CARR Biosystems have an API?
No public API is recorded for CARR Biosystems.
What industry is CARR Biosystems in?
CARR Biosystems's product category is Bioprocessing Centrifuge Equipment. Its primary akta.pro industry code is EUAAAIAN, Biorefinery Co-product Recovery, Purification & Separation (Downstream Processing Systems). Its SIC code is 3560.